Candace L. Haddox, MD

Dana Farber Cancer Institute
Boston, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• Paper 77 - A RANDOMIZED PHASE III TRIAL OF DOXORUBICIN + PEMBROLIZUMAB VERSUS DOXORUBICIN ALONE FOR TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND RELATED POORLY DIFFERENTIATED SARCOMAS: ECOG-ACRIN EA7222

  Saturday, November 16, 2024
  9:00 AM – 10:00 AM PST